$DXCM
DEXCOM INC Stock $dxcm

$dxcm Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-K Financial Statement

#000109355715000040 Filed on February 25, 2015

Income Statement

Concept	2013 Q4	2013 Q3	2013 Q2
Revenue	$51.70M	$42.90M	$35.80M
YoY Change	55.26%	85.71%	52.34%
Cost Of Revenue	$17.60M	$15.30M	$13.90M
YoY Change	12.1%	4.08%	13.93%
Gross Profit	$34.10M	$27.60M	$21.90M
YoY Change	94.86%	228.57%	95.54%
Gross Profit Margin	65.96%	64.34%	61.17%
Selling, General & Admin	$23.80M	$21.60M	$20.70M
YoY Change	38.37%	40.26%	30.19%
% of Gross Profit	69.79%	78.26%	94.52%
Research & Development	$12.60M	$11.80M	$11.10M
YoY Change	44.83%	14.56%	11.0%
% of Gross Profit	36.95%	42.75%	50.68%
Depreciation & Amortization	$1.900M	$1.700M	$1.600M
YoY Change	5.56%	-19.05%	6.67%
% of Gross Profit	5.57%	6.16%	7.31%
Operating Expenses	$36.40M	$33.40M	$31.80M
YoY Change	40.54%	29.96%	22.78%
Operating Profit	-$2.300M	-$5.800M	-$9.900M
YoY Change	-72.62%	-66.47%	-32.65%
Interest Expense	-$300.0K	$200.0K	$200.0K
YoY Change	50.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.600M	-$6.000M	-$10.10M
YoY Change	-69.41%	-65.32%	-31.29%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.600M	-$6.000M	-$10.10M
YoY Change	-69.41%	-65.32%	-31.29%
Net Earnings / Revenue	-5.03%	-13.99%	-28.21%
Basic Earnings Per Share
Diluted Earnings Per Share	-$35.96K	-$84.03K	-$142.5K
COMMON SHARES
Basic Shares Outstanding	71.78M shares	71.40M shares	70.90M shares
Diluted Shares Outstanding		71.40M shares	70.90M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$54.60M	$47.60M	$46.40M
YoY Change	12.11%	-10.76%	-24.19%
Cash & Equivalents	$43.20M	$33.40M	$28.20M
Short-Term Investments	$11.40M	$14.20M	$18.20M
Other Short-Term Assets	$3.400M	$2.500M	$2.800M
YoY Change	70.0%	-7.41%	12.0%
Inventory	$9.000M	$10.00M	$7.300M
Prepaid Expenses
Receivables	$26.10M	$21.60M	$17.70M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$93.10M	$81.70M	$74.20M
YoY Change	19.97%	8.11%	-11.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.70M	$19.70M	$19.10M
YoY Change	9.52%	5.84%	7.5%
Goodwill	$3.200M	$3.200M	$3.200M
YoY Change	0.0%	1.2%	1.2%
Intangibles	$3.600M	$3.700M	$3.900M
YoY Change	-14.29%	-14.21%	-12.6%
Long-Term Investments
YoY Change
Other Assets	$900.0K	$800.0K	$900.0K
YoY Change	-18.18%	716.33%	818.37%
Total Long-Term Assets	$29.40M	$28.40M	$28.10M
YoY Change	3.52%	4.32%	5.92%
TOTAL ASSETS
Total Short-Term Assets	$93.10M	$81.70M	$74.20M
Total Long-Term Assets	$29.40M	$28.40M	$28.10M
Total Assets	$122.5M	$110.1M	$102.3M
YoY Change	15.57%	7.11%	-7.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.200M	$3.800M	$2.800M
YoY Change	7.69%	0.0%	40.0%
Accrued Expenses	$25.00M	$21.20M	$16.40M
YoY Change	78.57%	37.66%	22.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.200M	$1.800M	$1.200M
YoY Change	1000.0%
Total Short-Term Liabilities	$32.10M	$27.40M	$21.10M
YoY Change	64.62%	34.29%	24.4%
LONG-TERM LIABILITIES
Long-Term Debt	$4.600M	$5.200M	$5.800M
YoY Change	-32.35%
Other Long-Term Liabilities	$1.700M	$2.800M	$3.100M
YoY Change	-19.05%	78.34%	99.87%
Total Long-Term Liabilities	$1.700M	$2.800M	$3.100M
YoY Change	-19.05%	78.34%	99.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.10M	$27.40M	$21.10M
Total Long-Term Liabilities	$1.700M	$2.800M	$3.100M
Total Liabilities	$38.40M	$35.40M	$30.00M
YoY Change	32.41%	57.03%	56.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$475.4M	-$472.8M	-$466.8M
YoY Change	6.69%	8.16%	11.17%
Common Stock	$559.5M	$547.5M	$539.1M
YoY Change	7.06%	5.81%	5.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$84.10M	$74.70M	$72.30M
YoY Change
Total Liabilities & Shareholders Equity	$122.5M	$110.1M	$102.3M
YoY Change	15.57%	7.11%	-7.44%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2013 Q2
OPERATING ACTIVITIES
Net Income	-$2.600M	-$6.000M	-$10.10M
YoY Change	-69.41%	-65.32%	-31.29%
Depreciation, Depletion And Amortization	$1.900M	$1.700M	$1.600M
YoY Change	5.56%	-19.05%	6.67%
Cash From Operating Activities	$4.400M	$1.600M	$900.0K
YoY Change	-141.51%	-126.67%	-114.29%
INVESTING ACTIVITIES
Capital Expenditures	-$2.300M	-$2.200M	-$2.000M
YoY Change	64.29%	-24.14%	-31.03%
Acquisitions
YoY Change
Other Investing Activities	$2.800M	$3.900M	$8.100M
YoY Change	-65.0%	-38.1%	-15.62%
Cash From Investing Activities	$500.0K	$1.700M	$6.100M
YoY Change	-92.42%	-50.0%	-10.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.900M	1.900M	2.300M
YoY Change	-32.88%	46.15%	360.0%
NET CHANGE
Cash From Operating Activities	4.400M	1.600M	900.0K
Cash From Investing Activities	500.0K	1.700M	6.100M
Cash From Financing Activities	4.900M	1.900M	2.300M
Net Change In Cash	9.800M	5.200M	9.300M
YoY Change	196.97%	-500.0%	830.0%
FREE CASH FLOW
Cash From Operating Activities	$4.400M	$1.600M	$900.0K
Capital Expenditures	-$2.300M	-$2.200M	-$2.000M
Free Cash Flow	$6.700M	$3.800M	$2.900M
YoY Change	-172.83%	-222.58%	-185.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001093557
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	77514635	shares
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014Q2	dei	Entity Public Float EntityPublicFloat	2916161528	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	DEXCOM INC
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2014	dei	Trading Symbol TradingSymbol	DXCM
CY2013Q4	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	26100000	USD
CY2014Q4	dxcm	Accounts Receivable Net Of Allowance And Sales Returns Current AccountsReceivableNetOfAllowanceAndSalesReturnsCurrent	42400000	USD
CY2013Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	1200000	USD
CY2014Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	1600000	USD
CY2013Q4	dxcm	Accrued Wages Bonus And Taxes AccruedWagesBonusAndTaxes	11300000	USD
CY2014Q4	dxcm	Accrued Wages Bonus And Taxes AccruedWagesBonusAndTaxes	12500000	USD
CY2013Q4	dxcm	Acquisition Related Contingent Consideration Short Term AcquisitionRelatedContingentConsiderationShortTerm	3600000	USD
CY2014Q4	dxcm	Acquisition Related Contingent Consideration Short Term AcquisitionRelatedContingentConsiderationShortTerm	0	USD
CY2012	dxcm	Business Acquisition Contingent Consideration Settlement BusinessAcquisitionContingentConsiderationSettlement	1100000	USD
CY2014Q4	dxcm	Business Acquisition Contingent Consideration Settlement Shares BusinessAcquisitionContingentConsiderationSettlementShares	89300	shares
CY2012	dxcm	Business Acquisition Contingent Consideration Settlement Shares Issued BusinessAcquisitionContingentConsiderationSettlementSharesIssued	89296	shares
CY2012Q1	dxcm	Business Combination Contingent Consideration Liability Shares BusinessCombinationContingentConsiderationLiabilityShares	357176	shares
CY2013Q4	dxcm	Clinical Trials ClinicalTrials	300000	USD
CY2014Q4	dxcm	Clinical Trials ClinicalTrials	400000	USD
CY2013Q4	dxcm	Contingent Consideration Fair Value Disclosure ContingentConsiderationFairValueDisclosure	4200000	USD
CY2014Q4	dxcm	Crosslicensingcontinuationfeeuponchangeofcontrol Crosslicensingcontinuationfeeuponchangeofcontrol	25000000	USD
CY2012Q4	dxcm	Debt Instrument Basis Spread On Treasury Variable Rate DebtInstrumentBasisSpreadOnTreasuryVariableRate	0.0694
CY2013Q4	dxcm	Deferred Tax Assets Goodwill And Intangible Assets Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssetsIntangibleAssets	1100000	USD
CY2014Q4	dxcm	Deferred Tax Assets Goodwill And Intangible Assets Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssetsIntangibleAssets	1200000	USD
CY2012	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	5000000	USD
CY2013	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	1800000	USD
CY2014	dxcm	Development And Other Cost Of Sales DevelopmentAndOtherCostOfSales	600000	USD
CY2012	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	6900000	USD
CY2013	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	2900000	USD
CY2014	dxcm	Development Grant And Other Revenue DevelopmentGrantAndOtherRevenue	2100000	USD
CY2014	dxcm	Employee Purchase Price Floor Percentage EmployeePurchasePriceFloorPercentage	0.85
CY2013Q4	dxcm	Employee Stock Purchase Plan Espp Shares In Espp EmployeeStockPurchasePlanEsppSharesInEspp	2600000	shares
CY2014Q4	dxcm	Employee Stock Purchase Plan Espp Shares In Espp EmployeeStockPurchasePlanEsppSharesInEspp	2500000	shares
CY2014	dxcm	Equity Incentive Plan Grant Date Fair Market Value Floor Percentage EquityIncentivePlanGrantDateFairMarketValueFloorPercentage	1.00
CY2012	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	700000	USD
CY2013	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	2500000	USD
CY2014	dxcm	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	-200000	USD
CY2014	dxcm	In Money Options Maximum Exercise Price InMoneyOptionsMaximumExercisePrice	55.05
CY2012	dxcm	Increase Decrease In Restricted Cash Investing And Financing Activities IncreaseDecreaseInRestrictedCashInvestingAndFinancingActivities	-100000	USD
CY2013	dxcm	Increase Decrease In Restricted Cash Investing And Financing Activities IncreaseDecreaseInRestrictedCashInvestingAndFinancingActivities	0	USD
CY2014	dxcm	Increase Decrease In Restricted Cash Investing And Financing Activities IncreaseDecreaseInRestrictedCashInvestingAndFinancingActivities	0	USD
CY2014	dxcm	Increase In Shares Reserved For Employee Stock Purchase Plan Percentage IncreaseInSharesReservedForEmployeeStockPurchasePlanPercentage	0.01
CY2014	dxcm	Increase In Shares Reserved For Equity Incentive Plans Percentage IncreaseInSharesReservedForEquityIncentivePlansPercentage	0.03
CY2014	dxcm	Maturity Threshold Of Investments Classified To Cash Equivalents MaturityThresholdOfInvestmentsClassifiedToCashEquivalents	90
CY2014	dxcm	Net Operating Losses And Tax Credit Carryforwards Limitations On Use Ownership Change Period NetOperatingLossesAndTaxCreditCarryforwardsLimitationsOnUseOwnershipChangePeriod	P3Y
CY2014	dxcm	Net Operating Losses And Tax Credit Carryforwards Limitations On Use Ownership Changes NetOperatingLossesAndTaxCreditCarryforwardsLimitationsOnUseOwnershipChanges	0.50
CY2014	dxcm	Number Of Purchase Periods Within Offering Period NumberOfPurchasePeriodsWithinOfferingPeriod	2
CY2014	dxcm	Numberofdaysacrosslicensingcontinuationfeeisdueuponchangeofcontrol Numberofdaysacrosslicensingcontinuationfeeisdueuponchangeofcontrol	P30D
CY2014	dxcm	Numberofdaysthecrosslicenseexpiresuponchangeofcontrolwhencrosslicensingcontinuationfeeisnotpaid Numberofdaysthecrosslicenseexpiresuponchangeofcontrolwhencrosslicensingcontinuationfeeisnotpaid	P30D
CY2014	dxcm	Offering Period Months OfferingPeriodMonths	P12M
CY2014	dxcm	Offering Periods Frequency OfferingPeriodsFrequency	P6M
CY2014	dxcm	Options In Money Exercisable Number OptionsInMoneyExercisableNumber	3100000	shares
CY2014	dxcm	Options In Money Number OptionsInMoneyNumber	3100000	shares
CY2012	dxcm	Other Significant Noncash Transaction Valueof Sweetspot Contingent Conisederation Settlement OtherSignificantNoncashTransactionValueofSweetspotContingentConisederationSettlement	0	USD
CY2013	dxcm	Other Significant Noncash Transaction Valueof Sweetspot Contingent Conisederation Settlement OtherSignificantNoncashTransactionValueofSweetspotContingentConisederationSettlement	0	USD
CY2014	dxcm	Other Significant Noncash Transaction Valueof Sweetspot Contingent Conisederation Settlement OtherSignificantNoncashTransactionValueofSweetspotContingentConisederationSettlement	4000000	USD
CY2012	dxcm	Permanent Items PermanentItems	0.0084
CY2013	dxcm	Permanent Items PermanentItems	0.0364
CY2014	dxcm	Permanent Items PermanentItems	0.0080
CY2014	dxcm	Potential Rental Rate Adjustment Maximum PotentialRentalRateAdjustmentMaximum	0.04
CY2014	dxcm	Potential Rental Rate Adjustment Minimum PotentialRentalRateAdjustmentMinimum	0.025
CY2012Q4	dxcm	Prime Rate Plus PrimeRatePlus	0.005
CY2014	dxcm	Purchase Date Frequency Months PurchaseDateFrequencyMonths	P6M
CY2014	dxcm	Purchase Period Months PurchasePeriodMonths	P6M
CY2014	dxcm	Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm	P1Y
CY2013	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	500000	USD
CY2014	dxcm	Researchand Development Arrangement Grants Received During Period ResearchandDevelopmentArrangementGrantsReceivedDuringPeriod	2500000	USD
CY2013Q3	dxcm	Researchand Development Arrangement Valueof Grant ResearchandDevelopmentArrangementValueofGrant	4000000	USD
CY2014	dxcm	Sales Return Coverage Period SalesReturnCoveragePeriod	P30D
CY2013Q4	dxcm	Share Based Compensation Arrangement By Share Based Payment Award Awards Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsNonvestedWeightedAverageGrantDateFairValue	4600000
CY2014Q4	dxcm	Share Based Compensation Arrangement By Share Based Payment Award Awards Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsNonvestedWeightedAverageGrantDateFairValue	0
CY2014	dxcm	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue	0
CY2014	dxcm	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriod	100000	shares
CY2014	dxcm	Share Based Compensation Excess Tax Benefits ShareBasedCompensationExcessTaxBenefits	63900000	USD
CY2013	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	4100000	USD
CY2014	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	5200000	USD
CY2013Q4	dxcm	Stock Options Reserved For Future Grant StockOptionsReservedForFutureGrant	500000	shares
CY2014Q4	dxcm	Stock Options Reserved For Future Grant StockOptionsReservedForFutureGrant	300000	shares
CY2012Q4	dxcm	Term Loan Advances Aggregate Amount TermLoanAdvancesAggregateAmount	7000000	USD
CY2012Q4	dxcm	Term Loan Debt TermLoanDebt	20000000	USD
CY2014	dxcm	Unused Expired Federal Income Tax Credits UnusedExpiredFederalIncomeTaxCredits	2100000	USD
CY2012	dxcm	Valuation Allowances And Reserves Write Offs And Adjustments ValuationAllowancesAndReservesWriteOffsAndAdjustments	-700000	USD
CY2013	dxcm	Valuation Allowances And Reserves Write Offs And Adjustments ValuationAllowancesAndReservesWriteOffsAndAdjustments	-1400000	USD
CY2014	dxcm	Valuation Allowances And Reserves Write Offs And Adjustments ValuationAllowancesAndReservesWriteOffsAndAdjustments	-2600000	USD
CY2014Q4	dxcm	Working Capital WorkingCapital	105300000	USD
CY2013Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	14100000	USD
CY2014Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	20400000	USD
CY2013Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4200000	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	9900000	USD
CY2013Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	28800000	USD
CY2014Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	46800000	USD
CY2013Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	26100000	USD
CY2014Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	42400000	USD
CY2012	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-800000	USD
CY2013	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-300000	USD
CY2014	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-100000	USD
CY2013Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1100000	USD
CY2014Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1500000	USD
CY2013Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	2700000	USD
CY2014Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	3200000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	26600000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32800000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	559500000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	638000000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18400000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24800000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50500000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18400000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24600000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50000000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2700000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4400000	USD
CY2012	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	100000	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	400000	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	300000	USD
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2013	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10400000	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9400000	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7300000	shares
CY2013Q4	us-gaap	Assets Assets	122500000	USD
CY2014Q4	us-gaap	Assets Assets	184600000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	93100000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	145900000	USD
CY2013Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8100000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43200000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71800000	USD
CY2013Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11400000	USD
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11400000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11800000	USD
CY2012Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2200000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2600000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	28600000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	11800000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5500000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	35100000	USD
CY2014Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	83600000	USD
CY2013Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	28700000	USD
CY2014Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	54300000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12600000	shares
CY2014Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10100000	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72800000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	77600000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72500000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	77300000	shares
CY2013Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2014Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54500000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29800000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22400000	USD
CY2012	us-gaap	Cost Of Goods Sold CostOfGoodsSold	48300000	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	58100000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	82300000	USD
CY2012	us-gaap	Cost Of Revenue CostOfRevenue	53300000	USD
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	59900000	USD
CY2014	us-gaap	Cost Of Revenue CostOfRevenue	82900000	USD
CY2012Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2016-11-01
CY2014Q4	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	15000000	USD
CY2012Q4	us-gaap	Debt Instrument Unused Borrowing Capacity Amount DebtInstrumentUnusedBorrowingCapacityAmount	13000000	USD
CY2012	us-gaap	Debt Issuance Costs DebtIssuanceCosts	1100000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	700000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	700000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	166000000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	169900000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	-100000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	-100000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	132800000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	132200000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5400000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	7300000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	9000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	12200000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	15500000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	7200000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	5000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	164700000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	169000000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1400000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	1000000	USD
CY2014	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.90
CY2012	us-gaap	Depreciation Depreciation	6100000	USD
CY2013	us-gaap	Depreciation Depreciation	6400000	USD
CY2014	us-gaap	Depreciation Depreciation	7800000	USD
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6600000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7000000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8400000	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.79
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0228
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0004
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0066
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2976
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.4515
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1924
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0213
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0711
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0166
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0301
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0223
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.1593
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0115
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0008
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0397
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0274
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0270
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0156
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0143
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0617
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0750
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15100000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17200000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	15100000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	17200000	USD
CY2014Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	105100000	USD
CY2013	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2500000	USD
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-200000	USD
CY2012Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1700000	USD
CY2013Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	4200000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	500000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	500000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	300000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	300000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	500000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	500000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2600000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	3200000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	3200000	USD
CY2012	us-gaap	Gross Profit GrossProfit	46600000	USD
CY2013Q1	us-gaap	Gross Profit GrossProfit	16500000	USD
CY2013Q2	us-gaap	Gross Profit GrossProfit	21900000	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	27600000	USD
CY2013Q4	us-gaap	Gross Profit GrossProfit	34100000	USD
CY2013	us-gaap	Gross Profit GrossProfit	100100000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	29800000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	39900000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	47200000	USD
CY2014Q4	us-gaap	Gross Profit GrossProfit	59400000	USD
CY2014	us-gaap	Gross Profit GrossProfit	176300000	USD
CY2012	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2013	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2014	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	200000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-55800000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29800000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22300000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.17
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.08
CY2014Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.07
CY2014Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.02
CY2014Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.17
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.09
CY2014Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.08
CY2014Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.02
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1300000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	300000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2400000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8300000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7000000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6500000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16300000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	100000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1200000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2012	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2400000	USD
CY2013	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5800000	USD
CY2014	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2200000	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-700000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1600000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7000000	USD
CY2012	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	500000	USD
CY2013	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	-300000	USD
CY2014	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	400000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	800000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1400000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	400000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3600000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2700000	USD
CY2012	us-gaap	Interest And Other Income InterestAndOtherIncome	100000	USD
CY2013	us-gaap	Interest And Other Income InterestAndOtherIncome	0	USD
CY2014	us-gaap	Interest And Other Income InterestAndOtherIncome	0	USD
CY2012	us-gaap	Interest Expense InterestExpense	200000	USD
CY2013	us-gaap	Interest Expense InterestExpense	900000	USD
CY2014	us-gaap	Interest Expense InterestExpense	800000	USD
CY2012	us-gaap	Interest Paid InterestPaid	0	USD
CY2013	us-gaap	Interest Paid InterestPaid	500000	USD
CY2014	us-gaap	Interest Paid InterestPaid	400000	USD
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3900000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7400000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	9000000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	16000000	USD
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4800000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	7600000	USD
CY2013Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	300000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1000000	USD
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2500000	USD
CY2013	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3000000	USD
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	3600000	USD
CY2014	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P5Y
CY2014	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P3Y
CY2013Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	700000	USD
CY2014Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	700000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	38400000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	44400000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	122500000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	184600000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32100000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40600000	USD
CY2012Q4	us-gaap	Line Of Credit LineOfCredit	15000000	USD
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	4600000	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2300000	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	2300000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10200000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11800000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21800000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28400000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	20900000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16800000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33100000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2400000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	23600000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-54500000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-11100000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-10100000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-6000000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-2600000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-29800000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-12500000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-6000000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-5200000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	1300000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-22400000	USD
CY2014	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2012	us-gaap	Operating Expenses OperatingExpenses	102300000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	27400000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	31800000	USD
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	33400000	USD
CY2013Q4	us-gaap	Operating Expenses OperatingExpenses	36400000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	129000000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	42100000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	45700000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	52200000	USD
CY2014Q4	us-gaap	Operating Expenses OperatingExpenses	57800000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	197800000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-55700000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-28900000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-21500000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	32700000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	3100000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	5200000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5000000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4000000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3600000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	11800000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4800000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8500000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	900000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	600000	USD
CY2012	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2013	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2014	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2012	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2013	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2014	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1700000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1500000	USD
CY2012	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2013	us-gaap	Other Noncash Expense OtherNoncashExpense	200000	USD
CY2014	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2012	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	6100000	USD
CY2013	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	USD
CY2014	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	USD
CY2012	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	66400000	USD
CY2013	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	16300000	USD
CY2014	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	13800000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9500000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7900000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16200000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000.0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2014Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3400000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3900000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3600000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12000000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24000000	USD
CY2012	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	6600000	USD
CY2013	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2012	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	104300000	USD
CY2013	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	45100000	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	13200000	USD
CY2013	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	3500000	USD
CY2014	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	4800000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47300000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	64000000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20700000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31200000	USD
CY2014Q4	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	18000000	USD
CY2012	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2013	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	200000	USD
CY2014	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2200000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	38300000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	44800000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69400000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1000000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1000000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1000000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1000000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-475400000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-497800000	USD
CY2013Q1	us-gaap	Revenues Revenues	29600000	USD
CY2013Q2	us-gaap	Revenues Revenues	35800000	USD
CY2013Q3	us-gaap	Revenues Revenues	42900000	USD
CY2013Q4	us-gaap	Revenues Revenues	51700000	USD
CY2014Q1	us-gaap	Revenues Revenues	47100000	USD
CY2014Q2	us-gaap	Revenues Revenues	58800000	USD
CY2014Q3	us-gaap	Revenues Revenues	69000000	USD
CY2014Q4	us-gaap	Revenues Revenues	84300000	USD
CY2012	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	93000000	USD
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	157100000	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	257100000	USD
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	99900000	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	160000000	USD
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	259200000	USD
CY2013Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	2200000	USD
CY2014Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	2300000	USD
CY2013Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	4600000	USD
CY2014Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	2300000	USD
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64000000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	84200000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	128400000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	18400000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	24600000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	50000000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3600000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	4200000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate	0.10
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3100000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7950000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2700000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	29800000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	99000000	USD
CY2012	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	5000000	USD
CY2012	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	2100000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	11530000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	147500000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5900000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3100000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7940000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7950000
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	68960	shares
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	89114	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	93246	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	106415	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	64563	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	70494	shares
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7920000
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	147500000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y6M12D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M12D
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3700000	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1300000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	400000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	4600000
CY2012Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	300000	USD
CY2013Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	900000	USD
CY2014Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1300000	USD
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2800000	shares
CY2013	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	10200000	USD
CY2014	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	21400000	USD
CY2012	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1500000	USD
CY2013	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1900000	USD
CY2014	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2600000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	104500000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	77000000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	84100000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	140200000	USD
CY2014	us-gaap	Tax Credit Carryforward Expiration Date TaxCreditCarryforwardExpirationDate	2020-01-01
CY2014Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	300000	USD
CY2014Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	1000000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4400000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4800000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6200000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7600000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	500000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	900000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1400000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	500000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	100000	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1300000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0	USD
CY2012Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1200000	USD
CY2013Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	2600000	USD
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	4300000	USD
CY2010Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	600000	USD
CY2012	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	1200000	USD
CY2013	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	2700000	USD
CY2014	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	4000000	USD
CY2012	us-gaap	Valuation Allowances And Reserves Recoveries ValuationAllowancesAndReservesRecoveries	100000	USD
CY2013	us-gaap	Valuation Allowances And Reserves Recoveries ValuationAllowancesAndReservesRecoveries	100000	USD
CY2014	us-gaap	Valuation Allowances And Reserves Recoveries ValuationAllowancesAndReservesRecoveries	300000	USD
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	68700000	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71100000	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	75200000	shares
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, short-term investment securities, and accounts receivable. We limit our exposure to credit loss by placing our cash with high credit quality financial institutions. We have established guidelines relative to diversification of our cash and investment securities and their maturities that are intended to secure safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates and changes in our operations and financial position. The following table summarizes customers who accounted for </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> or more of net accounts receivable:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td width="68%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="15%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer A</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19%</font></div></td></tr><tr><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17%</font></div></td></tr></table></div></div></div>
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring (“CGM”) systems for ambulatory use by people with diabetes and by healthcare providers in the hospital for the treatment of people with and without diabetes. Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “DexCom” refer to DexCom, Inc. and its subsidiaries.</font></div></div>
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, valuation of inventory, warranty accruals, clinical trial expenses, allowance for bad debt and share-based compensation expense. </font></div></div>

Files In Submission

Name	View Source	Status
0001093557-15-000040-index-headers.html	Edgar Link	pending
0001093557-15-000040-index.html	Edgar Link	pending
0001093557-15-000040.txt	Edgar Link	pending
0001093557-15-000040-xbrl.zip	Edgar Link	pending
dexcomsecondamendment_image1.jpg	Edgar Link	pending
dexcomsecondamendment_image2.jpg	Edgar Link	pending
dexcomsecondamendment_image3.jpg	Edgar Link	pending
dexcomsecondamendment_image4.jpg	Edgar Link	pending
dexcomsecondamendment_image5.gif	Edgar Link	pending
dxcm-12312014ex1033.htm	Edgar Link	pending
dxcm-12312014x10k.htm	Edgar Link	pending
dxcm-20141231.xml	Edgar Link	completed
dxcm-20141231.xsd	Edgar Link	pending
dxcm-20141231_cal.xml	Edgar Link	unprocessable
dxcm-20141231_def.xml	Edgar Link	unprocessable
dxcm-20141231_lab.xml	Edgar Link	unprocessable
dxcm-20141231_pre.xml	Edgar Link	unprocessable
dxcm12312014ex2101.htm	Edgar Link	pending
dxcm12312014ex2301.htm	Edgar Link	pending
dxcm12312014ex3101.htm	Edgar Link	pending
dxcm12312014ex3102.htm	Edgar Link	pending
dxcm12312014ex3201.htm	Edgar Link	pending
dxcm12312014ex3202.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
singledaycontinuousdataa01.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DXCM
DEXCOM INC Stock $dxcm

2013 Q4 Form 10-K Financial Statement

#000109355715000040 Filed on February 25, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM DEXCOM INC Stock $dxcm

2013 Q4 Form 10-K Financial Statement

#000109355715000040 Filed on February 25, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM
DEXCOM INC Stock $dxcm